Cardiovascular Systems Shareholders: Ownership Structure, Brands, and Acquisition History
Last updated: Sep-2026Ownership Structure
Stakes approximate based on latest filings.
Ownership Analysis
The defining fact about Cardiovascular Systems is that it ceased to be independent in 2023, when Abbott Laboratories acquired the entire company and folded it into its vascular-device operations. Abbott completed the acquisition on April 27, 2023, paying 20 dollars per share for a purchase price of about 851 million dollars, after which the former CSII shares were delisted and standalone governance and reporting ended. What that ownership represents is a strategic combination: Abbott, a global medical-device leader, acquired Cardiovascular Systems to add orbital-atherectomy technology, systems like the Diamondback 360 that break up arterial calcium to prepare vessels for stenting or angioplasty, to its cardiovascular and vascular portfolio, gaining a differentiated tool for treating heavily calcified coronary and peripheral arteries. For Cardiovascular Systems, the acquisition provided the scale, global sales reach, and resources of Abbott, which a specialized standalone device company could not match. For any investor, the practical implication is that the orbital-atherectomy business no longer exists as a separate investment; exposure to it is available only through Abbott shares, and its fortunes are subsumed into Abbott's vascular franchise. The relevant considerations are therefore about Abbott's growth of orbital atherectomy within its portfolio, the continued clinical adoption of the technology, and its competitive position against alternatives, rather than about any independent Cardiovascular Systems equity, which ended with the Abbott acquisition.
Direct Owners
Institutional Shareholders
Shareholder Analysis
Cardiovascular Systems no longer has public shareholders; its equity was acquired by Abbott in 2023 at 20 dollars per share, so the relevant analysis concerns the value the business contributes to Abbott rather than a standalone security. In its final full fiscal year as a public company, Cardiovascular Systems generated about 236 million dollars of revenue from orbital-atherectomy systems, and Abbott paid about 851 million dollars for the company. The appeal of the business as an Abbott asset is genuine: orbital atherectomy is a differentiated technology for treating heavily calcified arteries, a challenging clinical problem, and its Diamondback 360 and related systems address both coronary and peripheral artery disease, complementing Abbott's broader cardiovascular and vascular offerings and gaining the benefit of Abbott's global scale and sales reach. The value case rests on the continued clinical adoption of orbital atherectomy and Abbott's ability to grow it within its vascular franchise. The risks are those of the vascular-device market: competition from alternative vessel-preparation technologies, notably intravascular lithotripsy from Shockwave, now owned by Johnson and Johnson, and from device giants Boston Scientific, Medtronic and Philips, along with the clinical and regulatory demands of the field. For investors, the former Cardiovascular Systems is now a component of the Abbott investment case rather than a separate one, and its contribution depends on Abbott successfully growing orbital atherectomy against competing vessel-preparation technologies within its scaled vascular business.
Brands, Subsidiaries & Companies Owned
| Name | Type | Description |
|---|---|---|
| Diamondback 360 | Brand | Orbital atherectomy systems |
| Stealth 360 | Brand | Peripheral orbital atherectomy |
| ViperWire | Brand | Guide wires for orbital atherectomy |
| WIRION | Brand | Embolic protection system |
| Peripheral OAS | Product family | Peripheral artery treatment |
| Coronary OAS | Product family | Coronary artery treatment |
Portfolio Analysis
Cardiovascular Systems' competitive strength lay in its distinctive orbital-atherectomy technology, a specialized approach now marketed within Abbott's vascular portfolio. Its flagship products, the Diamondback 360 for coronary applications and the Stealth 360 for peripheral use, employ orbital atherectomy, a technique that uses a spinning, eccentrically mounted crown to sand away and break up the calcium that hardens diseased arteries, preparing vessels for stenting or angioplasty, supported by the ViperWire guide wires and the WIRION embolic-protection system. The strategy, as an independent company, was to establish orbital atherectomy as a preferred tool for treating heavily calcified coronary and peripheral arteries, a difficult clinical problem where calcium impedes conventional treatment, differentiating on the specific mechanism and clinical evidence of its technology. Cardiovascular Systems' competitive strength was this differentiated, purpose-built technology for vessel preparation in calcified arteries and the clinical relationships and evidence supporting it. Within Abbott, that technology gains global scale, sales reach and integration with a broader cardiovascular and vascular portfolio, potentially strengthening its clinical adoption. Its competitive identity was that of a specialized vessel-preparation technology company, and as part of Abbott its orbital-atherectomy franchise competes against alternative technologies like intravascular lithotripsy, with its prospects now depending on Abbott advancing the technology's clinical adoption within a scaled vascular business rather than on any independent competitive strategy.
Market Share & Competitors
Bubble size reflects relative market share.
| Company | Market Share | Revenue | Key Strength |
|---|---|---|---|
| Cardiovascular Systems ★ | Abbott Laboratories | $236.222M FY2022 | Orbital atherectomy systems business |
| Shockwave Medical | Johnson & Johnson | $730M FY2023 | Intravascular lithotripsy systems supplier |
| Boston Scientific | N/A | $17B FY2025 | Interventional cardiovascular device company |
| Medtronic | N/A | $34B FY2025 | Global cardiovascular and medical-device supplier |
| Philips | N/A | $20B FY2025 | Image-guided therapy and vascular-device supplier |
Competitive Analysis
Cardiovascular Systems competed in the interventional-cardiovascular device market with a specialized orbital-atherectomy technology, and as part of Abbott its franchise now competes within a scaled portfolio. Its most direct competitive challenge comes from alternative vessel-preparation technologies, notably intravascular lithotripsy from Shockwave Medical, now owned by Johnson and Johnson, which offers a different approach to treating calcified arteries, alongside the broad interventional-cardiovascular portfolios of Boston Scientific, Medtronic and Philips. Cardiovascular Systems' competitive footing rested on its differentiated orbital-atherectomy technology for the difficult clinical problem of heavily calcified arteries, the clinical evidence supporting it, and its focus on vessel preparation, and within Abbott it gains global scale, sales reach and integration with a broader vascular franchise. The pressures its franchise faces are competition from alternative technologies, particularly the fast-growing intravascular lithotripsy, from the large interventional-device companies, and the clinical and regulatory demands of demonstrating the value of its technology. As part of Abbott, orbital atherectomy competes as a differentiated vessel-preparation technology within a scaled vascular business, and its competitive prospects depend on Abbott advancing its clinical adoption against competing approaches like lithotripsy and leveraging Abbott's scale and relationships, its competitive position now shaped by Abbott's vascular strategy rather than by the independent competitive efforts of a standalone specialized device company, which ended when Abbott acquired it.
Acquisitions
Bubble size reflects relative deal value.
| Company Acquired | Deal Value | Year | Description |
|---|---|---|---|
| Cardiovascular Systems | $851M | 2023 | Abbott added orbital atherectomy technology to its vascular portfolio |
| WIRION technology | $10M plus milestones | 2019 | Added embolic protection technology |
Acquisitions Analysis
Cardiovascular Systems' corporate story culminated in its own acquisition by Abbott, though it had earlier made a small purchase to bolster its technology. As an independent company, it added the WIRION embolic-protection technology in 2019 for 10 million dollars plus milestones, expanding its procedure-support capabilities alongside its core orbital-atherectomy systems. The defining transaction, however, was Cardiovascular Systems becoming the target: on April 27, 2023, Abbott completed its acquisition of the company for about 851 million dollars at 20 dollars per share, ending its independent existence and folding the atherectomy portfolio into Abbott's vascular-device operations during 2024. That combination reflected Abbott's strategy of adding differentiated orbital-atherectomy technology to its cardiovascular portfolio, gaining a specialized tool for treating calcified arteries. Value creation involving the orbital-atherectomy business now depends not on any acquisitions it might make but on Abbott's growth of the technology within its vascular franchise and its ability to advance its clinical adoption. The relevant corporate action is the Abbott acquisition itself, which transformed Cardiovascular Systems from an independent specialized device company into part of a global medical-device leader, and its future contribution to value rests on how effectively Abbott integrates and grows the orbital-atherectomy portfolio within its broader vascular business rather than on any dealmaking of its own, its independent corporate life having ended with the Abbott purchase.
Acquisition Timeline
Merger & Spin-off History
Merger & Spin-off Analysis
Cardiovascular Systems' corporate structure ran from a reverse-merger public listing to full absorption by Abbott. The orbital-atherectomy business developed from 1989, incorporated in Delaware in 2000, and became publicly traded through a 2007 reverse merger, operating independently as a specialized device company and expanding its addressable market when its coronary system received United States approval in 2013. That independence ended with a change of ownership: on April 27, 2023, Abbott completed its acquisition of the company for about 851 million dollars, delisting the former CSII shares and ending standalone governance and reporting as the atherectomy portfolio was integrated into Abbott's vascular-device operations during 2024. The resulting structure places the orbital-atherectomy business inside Abbott's broader cardiovascular and vascular franchise as a wholly owned component rather than an independent company. That structural arc, a reverse-merger listing that created an independent public device company, followed by acquisition and absorption into a global device leader, defines Cardiovascular Systems' corporate history, and its structure today is that of an integrated part of Abbott rather than a standalone enterprise. Its structural future is determined by Abbott's organization and growth of its vascular business, with the orbital-atherectomy franchise a technology within a larger portfolio rather than a company with its own structure, its independent corporate existence having concluded with the 2023 Abbott acquisition.
Ownership History
Ownership History Analysis
Cardiovascular Systems' history runs from a specialized medical-device innovator to a component of Abbott's vascular franchise. The orbital-atherectomy technology began developing in 1989, the company incorporated in Delaware in 2000, and it became publicly traded through a 2007 reverse merger, building a business on its distinctive approach to treating calcified arteries. A pivotal milestone came in 2013, when its coronary orbital-atherectomy system received United States approval, expanding its addressable market beyond peripheral applications, and it added embolic-protection technology through the 2019 WIRION acquisition. As a focused device company competing against larger players and emerging alternatives, Cardiovascular Systems ultimately found a home within a device giant: Abbott acquired it on April 27, 2023, for about 851 million dollars at 20 dollars per share, delisting the shares and folding the atherectomy portfolio into its vascular operations. Generating about 236 million dollars of revenue in its final full year with roughly 725 employees, Cardiovascular Systems is now part of Abbott. Its history is that of a specialized innovator that developed a differentiated technology for a difficult clinical problem, built an independent public company on it, and was ultimately acquired to become part of a global medical-device leader's vascular franchise, its orbital-atherectomy technology continuing within Abbott while its independent corporate existence ended with the 2023 acquisition.
Ownership Explained
Cardiovascular Systems is a maker of orbital-atherectomy devices used to treat coronary and peripheral artery disease that, since 2023, is a wholly owned part of Abbott Laboratories rather than an independent public company. A St. Paul, Minnesota business whose orbital-atherectomy technology dates to 1989, it generated about 236 million dollars of revenue in its final full fiscal year as a public company and employed roughly 725 people, selling systems such as the Diamondback 360 that break up arterial calcium to prepare vessels for treatment. Abbott completed its acquisition on April 27, 2023, paying 20 dollars per share for a purchase price of about 851 million dollars, delisting the former CSII shares and folding the atherectomy portfolio into its vascular-device operations.
There is no longer an independent Cardiovascular Systems equity; the business belongs entirely to Abbott, which acquired it in 2023 to add orbital atherectomy to its vascular-device portfolio. That ownership reflects the strategic logic of a large medical-device company absorbing a specialized technology: Abbott gained a differentiated tool for treating heavily calcified arteries, complementing its broader cardiovascular and vascular offerings, while Cardiovascular Systems gained the scale, sales reach and resources of a global device leader. For investors, exposure to the orbital-atherectomy business is no longer available separately; it exists only within Abbott. The value of the former company as an Abbott asset rests on the continued clinical adoption of orbital atherectomy and Abbott's ability to grow it within its vascular franchise.